Condition deep-dive · 7 min read

IBS-C protocol — what supplements actually move stool in constipation-predominant IBS

Updated 2026-05-15 · Reviewed by SupplementScore editors · No sponsorships

IBS with constipation (IBS-C) sits at the intersection of slow transit, hard stool, and visceral hypersensitivity. The supplement layer is unusual for IBS in that several interventions have legitimate efficacy on stool form and frequency, while typical "gut health" probiotics often disappoint or worsen bloating. The cleanest interventions are mechanical (magnesium, soluble fibre, kiwifruit). Probiotic strain selection matters more here than in IBS-M — broad spectrum products can worsen the bloating component without moving the constipation.

Rule out structural and red-flag causes first. New-onset constipation in adults >50, blood in stool, unintended weight loss, family history of colorectal cancer, nocturnal symptoms, or progressive worsening warrant colonoscopy/specialist evaluation before reaching for supplements. Long-standing IBS-C with stable symptoms is the right context for the protocol below; new-onset is not.

What actually has trial evidence

Tier 1 evidence · Osmotic, replicated

Magnesium oxide (or magnesium hydroxide)

300–600 mg elemental at bedtime, titrate to soft formed stool

Oxide and hydroxide forms are the laxative magnesium forms — the same osmotic mechanism as polyethylene glycol but cheaper. The 2019 Mori RCT (n=34 IBS-C) showed magnesium oxide 1.5 g/day (≈ 900 mg elemental) significantly increased complete spontaneous bowel movements vs placebo. Take at night for a morning result; titrate down if stools become too loose. Avoid in significant renal impairment (magnesium accumulation). This is the cheapest and most underused IBS-C intervention.

Tier 1 evidence · IBS-C-friendly soluble fibre

Psyllium husk

3–10 g/day in divided doses, start at 3 g and titrate over 2 weeks

The Bijkerk 2009 BMJ trial (n=275 IBS patients) showed psyllium 10 g/day improved global IBS symptoms vs placebo at 12 weeks. Mechanism: water-binding gel that softens stool and adds bulk without the heavy fermentation of FOS/inulin. ACG IBS guidelines support soluble fibre (specifically psyllium) in IBS-C. Start low to avoid bloating; mix with adequate water.

Tier 2 evidence · Low-FODMAP-tolerable prebiotic

Partially hydrolysed guar gum (PHGG)

5–10 g/day titrated up over 3 weeks

PHGG ferments more slowly than inulin/FOS, producing less gas and bloating while still acting as a prebiotic and softening stool. Niv 2016 RCT (n=121 IBS) showed PHGG comparable to fibre on global IBS symptom improvement. A useful option for users who didn't tolerate psyllium or want a prebiotic effect on the microbiota without the FODMAP burden.

Tier 2 evidence · Food-form intervention

Kiwifruit (green Hayward, 2 fruits/day)

2 ripe green kiwifruit/day, eaten with breakfast

The Chey 2021 multicentre RCT compared green kiwifruit (2/day), psyllium (12 g/day), and prunes (100 g/day) in chronic constipation, finding all three increased complete spontaneous bowel movements vs no intervention, with kiwifruit showing the cleanest tolerability profile (less bloating). Useful as a food-form first-line or layered on top of magnesium. Actinidin protease activity also modestly aids protein digestion.

Tier 2 evidence · Strain-specific probiotic

Bifidobacterium lactis HN019 (or B. lactis BB-12)

≥10 billion CFU/day for 4–8 weeks

Among probiotic strains studied in IBS-C, Bifidobacterium lactis HN019 has the most consistent transit-time and stool-frequency signal (Waller 2011 RCT; subsequent meta-analyses). Avoid broad-spectrum 50-billion-CFU products without strain identification — they don't reliably target IBS-C and can worsen bloating. Saccharomyces boulardii has data in diarrhoeal IBS, not constipation.

Tier 2 evidence · Smooth-muscle relaxant

Peppermint oil (enteric-coated)

180–225 mg three times daily, enteric-coated

Targets visceral pain and bloating rather than transit specifically. ACG conditionally recommends for global IBS symptoms. Useful adjunct in IBS-C with prominent pain/bloating component. Caution with reflux — enteric coating is essential to avoid lower oesophageal sphincter relaxation and worsening reflux symptoms.

The lifestyle and behavioural base — usually higher yield than any supplement

Hydration target — 1.5–2 L/day; fibre without water makes constipation worse.
Toileting posture — squatty-stool-style hip flexion improves anorectal angle and decreases straining.
Morning routine — warm fluid + breakfast triggers the gastrocolic reflex; sit on the toilet 15–30 minutes post-breakfast even without urge.
Regular physical activity — 30 min/day moderate activity improves colonic transit; sedentary lifestyle is a major modifiable IBS-C factor.
Low-FODMAP trial — selectively — useful in mixed IBS-C with bloating, but not first-line for pure transit complaints. Reintroduce systematically.
Pelvic floor evaluation — dyssynergic defecation (paradoxical puborectalis contraction) is common in refractory IBS-C and is treated with biofeedback, not supplements. Ask about anorectal manometry referral if magnesium/fibre/kiwifruit don't help.
Medication review — opioids, anticholinergics, iron, calcium channel blockers, calcium supplements, GLP-1 agonists, and ondansetron all worsen constipation; review with prescribers.

What to skip

Inulin / FOS prebiotics — high-FODMAP fermentable substrate; worsens bloating in many IBS-C users. PHGG is the IBS-friendlier substitute.
Generic 50-billion CFU "wide-spectrum" probiotics — thin strain documentation, often Lactobacillus-heavy with no IBS-C-specific evidence; can worsen bloating.
Senna, cascara, aloe latex for daily use — stimulant laxatives are useful for rescue but not safe as a daily long-term IBS-C strategy (melanosis coli, dependence concerns at high chronic doses).
"Colon cleanse" / "detox" products — no IBS-C-specific evidence; some contain undisclosed senna or other stimulants.
Bentonite clay, activated charcoal as daily intervention — bind nutrients and medications; constipation effect itself is opposite of what's wanted.
"Adrenal fatigue" / "gut healing" 30-ingredient capsules — diluted ingredients, no IBS-C trial evidence for the combinations.
Magnesium glycinate / threonate alone for constipation — these are the non-laxative magnesium forms; useful for sleep/mood but not for moving stool. Oxide/hydroxide are the laxative forms.

What to track

The Bristol Stool Form Scale (target 3–4) and complete-spontaneous-bowel-movement (CSBM) frequency are the standard endpoints. Aim for ≥3 CSBM/week with type 3–4 stool form. Reassess at 4 weeks and 12 weeks. If still <3 CSBM/week on optimised magnesium + soluble fibre + kiwifruit + lifestyle base, that's the threshold to discuss prescription secretagogues (linaclotide, plecanatide, lubiprostone) or 5-HT4 agonists with your clinician.

Practical quick-start. Layer in this order, give each layer 2 weeks. (1) Hydration + morning toileting routine + 30 min/day activity. (2) Magnesium oxide 300 mg at bedtime, titrate to soft formed stool. (3) Psyllium 5 g/day with water, titrating up. (4) Add green kiwifruit 2/day or PHGG 5–10 g/day if psyllium not tolerated. (5) Strain-specific probiotic (B. lactis HN019) only if bloating is also prominent. Reassess at 12 weeks; escalate to clinical management if CSBM <3/week persists.

Sources

Mori H, et al. Magnesium oxide in constipation. Nutrients. 2021;13(2):421. PMID: 33525523
Bijkerk CJ, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. PMID: 19713235
Chey SW, et al. Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US patients with chronic constipation. Am J Gastroenterol. 2021;116(6):1304–1312. PMID: 34074830
Niv E, et al. Randomized clinical study: partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond). 2016;13:10. PMID: 26855666
Waller PA, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057–1064. PMID: 21663486
Lacy BE, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17–44. PMID: 33315591